ZuzanaTothovaMD

Hematologic Oncology

Clinical Fellow in Medicine, Dana-Farber Cancer Institute

Dr. Tothova is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
450 Brookline Avenue, D0259
Boston, MA 02115
Phone+1 617-632-2933

Fax+1 617-632-2933

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
Brigham and Women's HospitalResidency, Internal Medicine, 2009 - 2011
Harvard Medical SchoolClass of 2009

PubMed

854 citations
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis
Jihye Paik, Ramya Kollipara, Gerald C. Chu, Hongkai Ji, Yonghong Xiao
Cell. 2007-01-26
1219 citations
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress.
Zuzana Tothova, Ramya Kollipara, Brian J. P. Huntly, Benjamin H. Lee, Diego H. Castrillon
Cell. 2007-01-26
13 citations
Systematic profiling of conditional degron tag technologies for target validation studies.
Daniel P Bondeson, Zachary Mullin-Bernstein, Sydney Oliver, Thomas A Skipper, Thomas C Atack
Nature Communications. 2022-09-20

Abstracts/Posters

Talazoparib Treatment Preferentially Depletes Cohesin-Mutant Clones in New In Vivo Models of Cohesin-Mutant Myeloid Diseases
Zuzana Tothova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

A Community of ResearchersDecember 18th, 2020
Dana-Farber Receives $5 Million Gift to Create the Edward P. Evans Center for MDSSeptember 16th, 2019
Dana-Farber Physician Zuzana Tothova Receives Doris Duke Foundation Paragon Award for Research ExcellenceNovember 24th, 2023